Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b open-label safety study of Novartis meningococcal B recombinant vaccine in at-risk healthy adults
2011-003694-29Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of meningococcal group B vaccine (recombinant, adsorbed) in meningococcal disease, sponsored by Novartis. Primary endpoint: Safety of Novartis meningococcal B recombinant vaccine. Started Feb 2012; status: completed.
02
Drugs
meningococcal group B vaccine (recombinant, adsorbed)
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2011-003694-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003694-29.